Claims

Every tracked claim and what happened to it, newest first.

24,733 total · showing 24,701–24,733

• TeraWulf — Jon Gerlach Chief Financial Officer stated · 2006-03-23
• TeraWulf — Claude P. Piguet Executive Vice President stated · 2006-03-23
• TeraWulf — William C. Ulland CEO and Chairman stated · 2006-03-23
• TeraWulf — Form S-8 registration statement filed for stock plan stated · 2006-03-23
• TeraWulf — McGladrey & Pullen selected as independent auditor not_yet_verifiable · 2006-03-23
• Riot — Holding company restructuring stated · 2005-09-25
• Riot — Company name change to AspenBio Pharma, Inc. stated · 2005-09-25
• Riot — Authorized shares increase stated · 2005-09-25
• Riot — Stock Incentive Plan share increase stated · 2005-09-25
• Riot — Roger D. Hurst employment terminated stated · 2005-09-25
• Riot — David E. Welch joined Board of Directors stated · 2005-09-25
• Riot — Douglas I. Hepler joined Board of Directors stated · 2005-09-25
• Riot — Jeffrey G. McGonegal appointed CFO stated · 2005-09-25
• Riot — Richard G. Donnelly elected Director stated · 2005-09-25
• Riot — Richard G. Donnelly appointed President and CEO stated · 2005-09-25
• Riot — Antigen business acquisition from Vitro Diagnostics stated · 2005-09-25
• TeraWulf — Independent auditor retention for 2005 not_yet_verifiable · 2005-03-24
• TeraWulf — Board director elections for 2005 not_yet_verifiable · 2005-03-24
• Riot — Markets over 30 products to diagnostic test manufacturers and research facilities stated · 2004-09-13
• Riot — StayBred requires FDA approval or ANDA filing stated · 2004-09-13
• Riot — SurBred 15 antigen-based blood test not subject to FDA regulation stated · 2004-09-13
• Riot — Roger Hurst exclusive employment agreement stated · 2004-09-13
• Riot — Pipeline products in development stated · 2004-09-13
• Riot — StayBred recombinant luteinizing hormone for cattle pregnancy maintenance stated · 2004-09-13
• Riot — SurBred 15 early detection bovine pregnancy test stated · 2004-09-13
• Riot — License arrangements with three universities stated · 2004-09-13
• Riot — Merial exclusive marketing and distribution rights for SurBred 15 stated · 2004-09-13
• Riot — CFO appointment stated · 2004-04-04
• Riot — Director appointment stated · 2004-04-04
• Riot — Acquisition of antigen business from Vitro Diagnostics stated · 2004-03-23
• Riot — Douglas I. Hepler stock options stated · 2004-03-23
• Riot — Jeffrey G. McGonegal appointed Chief Financial Officer stated · 2004-03-23
• Riot — Douglas I. Hepler appointed to Board of Directors stated · 2004-03-23